Allegro Ophthalmics Reports Phase II Data for Luminate
Vicken Karageozian, MD, president and chief medical officer of Allegro Ophthalmics, reports on Phase II data of lead candidate Luminate as sequential and combination therapy with anti-VEGF therapy for treatment of diabetic macular edema. Twelve-week data he presents at OIS@ASRS 2017 show durability of action of Luminate, a synthetic anti-integrin drug that binds to multiple integrin inhibitors to block angiogenesis and inflammation.